Literature DB >> 32091921

Systemic Consequences of Pulmonary Hypertension and Right-Sided Heart Failure.

Stephan Rosenkranz1,2, Luke S Howard3, Mardi Gomberg-Maitland4, Marius M Hoeper5,6.   

Abstract

Pulmonary hypertension (PH) is a feature of a variety of diseases and continues to harbor high morbidity and mortality. The main consequence of PH is right-sided heart failure which causes a complex clinical syndrome affecting multiple organ systems including left heart, brain, kidneys, liver, gastrointestinal tract, skeletal muscle, as well as the endocrine, immune, and autonomic systems. Interorgan crosstalk and interdependent mechanisms include hemodynamic consequences such as reduced organ perfusion and congestion as well as maladaptive neurohormonal activation, oxidative stress, hormonal imbalance, and abnormal immune cell signaling. These mechanisms, which may occur in acute, chronic, or acute-on-chronic settings, are common and precipitate adverse functional and structural changes in multiple organs which contribute to increased morbidity and mortality. While the systemic character of PH and right-sided heart failure is often neglected or underestimated, such consequences place additional burden on patients and may represent treatable traits in addition to targeted therapy of PH and underlying causes. Here, we highlight the current state-of-the-art understanding of the systemic consequences of PH and right-sided heart failure on multiple organ systems, focusing on self-perpetuating pathophysiological mechanisms, aspects of increased susceptibility of organ damage, and their reciprocal impact on the course of the disease.

Entities:  

Keywords:  cognitive function; immune system; kidney dysfunction; liver dysfunction; pulmonary hypertension; right-sided heart failure; sleep

Year:  2020        PMID: 32091921     DOI: 10.1161/CIRCULATIONAHA.116.022362

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  28 in total

1.  Medical treatment of pulmonary hypertension in adults with congenital heart disease: updated and extended results from the International COMPERA-CHD Registry.

Authors:  Christian Opitz; Ekkehard Grünig; Stephan Rosenkranz; Ann-Sophie Kaemmerer; Matthias Gorenflo; Dörte Huscher; David Pittrow; Peter Ewert; Christine Pausch; Marion Delcroix; Hossein A Ghofrani; Marius M Hoeper; Rainer Kozlik-Feldmann; Andris Skride; Gerd Stähler; Carmine Dario Vizza; Elena Jureviciene; Dovile Jancauskaite; Lina Gumbiene; Ralf Ewert; Ingo Dähnert; Matthias Held; Michael Halank; Dirk Skowasch; Hans Klose; Heinrike Wilkens; Katrin Milger; Christian Jux; Martin Koestenberger; Laura Scelsi; Eva Brunnemer; Michael Hofbeck; Silvia Ulrich; Anton Vonk Noordegraaf; Tobias J Lange; Leonhard Bruch; Stavros Konstantinides; Martin Claussen; Judith Löffler-Ragg; Hubert Wirtz; Christian Apitz; Rhoia Neidenbach; Sebastian Freilinger; Attila Nemes
Journal:  Cardiovasc Diagn Ther       Date:  2021-12

Review 2.  Comprehensive Assessment of Fluid Status by Point-of-Care Ultrasonography.

Authors:  Eduardo R Argaiz; Abhilash Koratala; Nathaniel Reisinger
Journal:  Kidney360       Date:  2021-05-27

3.  Plasma Cell-Free DNA Predicts Survival and Maps Specific Sources of Injury in Pulmonary Arterial Hypertension.

Authors:  Sean Agbor-Enoh; Michael A Solomon; Samuel B Brusca; Jason M Elinoff; Yvette Zou; Moon Kyoo Jang; Hyesik Kong; Cumhur Y Demirkale; Junfeng Sun; Fayaz Seifuddin; Mehdi Pirooznia; Hannah A Valantine; Carl Tanba; Abhishek Chaturvedi; Grace M Graninger; Bonnie Harper; Li-Yuan Chen; Justine Cole; Manreet Kanwar; Raymond L Benza; Ioana R Preston
Journal:  Circulation       Date:  2022-08-25       Impact factor: 39.918

4.  Abnormal Liver Function Tests Were Related to Short- and Long-Term Prognosis in Critically Ill Patients With Primary Pulmonary Hypertension.

Authors:  Dayu Wang; Suiqing Huang; Guangtao Xu; Sha Wu; Zhen Liu; Long Xu; Bo Hu; Jian Hou
Journal:  Front Cardiovasc Med       Date:  2022-06-02

5.  Right ventricular myocardial energetic model for evaluating right heart function in pulmonary arterial hypertension.

Authors:  Jacqueline V Scott; Tanuf U Tembulkar; Meng-Lin Lee; Bradley T Faliks; Kelly L Koch; Anton Vonk-Noordegraaf; Keith E Cook
Journal:  Physiol Rep       Date:  2022-05

6.  Puerarin-V prevents the progression of hypoxia- and monocrotaline-induced pulmonary hypertension in rodent models.

Authors:  Di Chen; Hui-Fang Zhang; Tian-Yi Yuan; Shu-Chan Sun; Ran-Ran Wang; Shou-Bao Wang; Lian-Hua Fang; Yang Lyu; Guan-Hua Du
Journal:  Acta Pharmacol Sin       Date:  2022-02-21       Impact factor: 7.169

Review 7.  The updated view on induced pluripotent stem cells for cardiovascular precision medicine.

Authors:  Yong Wang; Wei Lei; Jingsi Yang; Xuan Ni; Lingqun Ye; Zhenya Shen; Shijun Hu
Journal:  Pflugers Arch       Date:  2021-02-17       Impact factor: 3.657

8.  A Novel Non-Invasive Device for the Assessment of Central Venous Pressure in Hospital, Office and Home.

Authors:  Emanuela Marcelli; Laura Cercenelli; Barbara Bortolani; Saverio Marini; Luca Arfilli; Alessandro Capucci; Gianni Plicchi
Journal:  Med Devices (Auckl)       Date:  2021-05-13

9.  Pulmonary Arterial Hypertension: Diagnosis, Treatment, and Novel Advances.

Authors:  Bradley A Maron; Steven H Abman; C Greg Elliott; Robert P Frantz; Rachel K Hopper; Evelyn M Horn; Mark R Nicolls; Oksana A Shlobin; Sanjiv J Shah; Gabor Kovacs; Horst Olschewski; Erika B Rosenzweig
Journal:  Am J Respir Crit Care Med       Date:  2021-06-15       Impact factor: 30.528

Review 10.  PTEN as a Therapeutic Target in Pulmonary Hypertension Secondary to Left-heart Failure: Effect of HO-3867 and Supplemental Oxygenation.

Authors:  Yazhini Ravi; Chittoor B Sai-Sudhakar; Periannan Kuppusamy
Journal:  Cell Biochem Biophys       Date:  2021-06-16       Impact factor: 2.194

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.